Kozobolis Vassilios, Konstantinidis Aristeidis, Sideroudi Haris, Teus Miguel
Department of Ophthalmology, Democritus University of Thrace, Alexandroupolis, Greece,
Eye Institute of Thrace (EIT), Democritus University of Thrace, Alexandroupolis, Greece,
Clin Ophthalmol. 2018 Nov 23;12:2393-2398. doi: 10.2147/OPTH.S172822. eCollection 2018.
To compare the hypotensive effect of travoprost 0.004%/timolol 0.5% fixed combination (TTFC) to the concomitant use of travoprost and timolol 0.1% gel formulation (Trav + Geltim).
Thirty-three patients (62 eyes) were enrolled and divided into two groups. Patients in group 1 (31 eyes) received the TTFC and patients in group 2 (31 eyes) received the concomitant treatment with Trav + Geltim. Patients on previous antiglaucoma treatment discontinued their drops for 2-4 weeks before starting their new treatment (TTFC or Trav + Geltim). The drops were instilled in the evening in group 1 and in group 2, the prostaglandin was installed in the evening, and timolol in the morning. IOP was measured at 1 and 3 months after the initiation of treatment at four time points during the day (09:00, 12:00, 15:00, and 18:00).
Both groups showed significant IOP reduction from baseline at all time points at 1 and 3 months. When the two groups were compared, group 2 showed slightly better hypotensive effect that reached statistical significance only at the 18:00 time point at both 1 and 3 months.
Both the TTFC and the concomitant use of the travoprost/timolol gel showed similar hypotensive effect with the latter being slightly more potent in reducing the IOP.
比较0.004%曲伏前列素/0.5%噻吗洛尔固定复方制剂（TTFC）与曲伏前列素和0.1%噻吗洛尔凝胶制剂联合使用（曲伏前列素+噻吗洛尔凝胶）的降压效果。
纳入33例患者（62只眼）并分为两组。第1组（31只眼）患者接受TTFC治疗，第2组（31只眼）患者接受曲伏前列素+噻吗洛尔凝胶联合治疗。之前接受抗青光眼治疗的患者在开始新治疗（TTFC或曲伏前列素+噻吗洛尔凝胶）前停用滴眼液2 - 4周。第1组在晚上滴注滴眼液，第2组晚上滴注前列腺素，早上滴注噻吗洛尔。在治疗开始后1个月和3个月的白天4个时间点（09:00、12:00、15:00和18:00）测量眼压。
两组在1个月和3个月的所有时间点眼压均较基线显著降低。两组比较时，第2组降压效果略好，仅在1个月和3个月的18:00时间点达到统计学意义。
TTFC和曲伏前列素/噻吗洛尔凝胶联合使用均显示出相似的降压效果，后者在降低眼压方面略强。
